EXAI News and Press, Exscientia Limited From 06/06/24

— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology ...

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England G...

2024-05-27 09:40:00 ET Summary Google DeepMind and Isomorphic Labs have recently unveiled an exciting new breakthrough, AlphaFold 3. AlphaFold 3 employs advanced AI algorithms to accurately model molecular structures and interactions. Beyond drug discovery, AlphaFold 3’...

2024-05-22 00:03:06 ET Summary Exscientia plc's stock has underperformed the biotechnology and IT sectors, despite owning a tech platform attracting big pharma. The company uses AI to accelerate drug development and reduce time to market, potentially improving success rates. T...

2024-05-21 11:27:43 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...

2024-05-21 07:03:04 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...

CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...

Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025 , respectively ...

2024-05-20 11:21:23 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 18, 2024) - Faruqi & Faruqi, LLP, a leading national ...